Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220893 · ClinicalTrials.gov registry record · NA
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 3,023
- Enrollment target
NCT03220893: Completed NA study, sponsored by Mayo Clinic.
NCT03220893 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 3,023 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03220893, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,023 participants
- Enrollment target
Study Summary
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat. Molecular breast imaging (MBI) uses an injection of a small amount of radioactive material that is taken up in tissues of the body that are actively changing, such as breast cancer. A specialized camera, called a gamma camera, takes pictures of the gamma rays emitted by this material. MBI may detect cancers that are not visible on mammograms. This study may help researchers determine how MBI testing compares to DBT screening.
Primary Outcome
Compare the rate of detection of invasive cancers between DBT alone versus (vs.) the combination of digital breast tomosynthesis (DBT) with supplemental molecular breast imaging (MBI) at initial (year 1) screening. For each modality, the detection rate of invasive cancers will be estimated as the proportion of participants in the analysis set who had an invasive cancer detected by the modality and verified by pathology.
Interventions
- RADIATION Scintimammography
- PROCEDURE Digital Breast Tomosynthesis (DBT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,023 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2024-11-01 |
| Phase | NA |
What the finished NCT03220893 record still lists
NCT03220893 is an interventional study that assigns participants to a tested intervention. Its 3,023 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 2 interventions - of which Scintimammography is the first listed.
NCT03220893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03220893 about?
NCT03220893 is a clinical study titled "Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue". This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat. Molecular breast imaging (MBI) uses an injection of a small amount of r...
What is the current status of trial NCT03220893?
This trial is currently completed. It is a NA study. The enrollment target is 3,023 participants. The study started on 2017-06-14. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT03220893?
The interventions under investigation include: Scintimammography (RADIATION), Digital Breast Tomosynthesis (DBT) (PROCEDURE).
Who is sponsoring clinical trial NCT03220893?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03220893's enrollment target sits among peer trials
3,023 40th of 2000 higher than 1,961 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI